Eli Lilly and Business LLY will launch its fourth-quarter monetary outcomes, before the opening bell, on Thursday, Feb. 6, 2025.
Experts anticipate the Indianapolis, Indiana-based business to report quarterly incomes at $5.08 per share, up from $2.49 per share in the year-ago duration. Eli Lilly jobs quarterly profits of $13.43 billion, compared to $9.35 billion a year previously, according to information from Benzinga Pro.
In January, prior to the JP Morgan health care conference, Eli Lilly revealed that it anticipates 2024 full-year around the world profits to be around $45.0 billion, representing a 32% development compared to the previous year vs. the agreement of $45.50 billion.
Eli Lilly shares got 2% to close at $842.18 on Wednesday.
Benzinga readers can access the current expert rankings on the Expert Stock Scores page. Readers can arrange by stock ticker, business name, expert company, ranking modification or other variables.
Let’s take a look at how Benzinga’s most-accurate experts have actually ranked the business in the current duration.
- Wells Fargo expert Mohit Bansal preserved an Obese ranking and cut the rate target from $1,000 to $970 on Jan. 28, 2025. This expert has a precision rate of 72%.
- B of A Securities expert Tim Anderson restored a Buy ranking and a rate target of $997 on Dec. 10, 2024. This expert has a precision rate of 65%.
- Barclays expert Carter Gould preserved an Obese ranking and cut the rate target from $1,025 to $975 on Oct. 31, 2024. This expert has a precision rate of 60%.
- Morgan Stanley expert Terence Flynn repeated an Obese ranking with a rate target of $1,106 on Aug. 27, 2024. This expert has a precision rate of 67%.
- BMO Capital expert Evan Seigerman preserved an Outperform ranking and raised the rate target from $1,001 to $1,101 on Aug. 9, 2024. This expert has a precision rate of 62%.
Thinking about purchasing LLY stock? Here’s what experts believe:
Read This Next:
Summary Score:
Speculative
Market News and Data gave you by Benzinga APIs